A method of treating a subject with Hutchinson-Gilford progeria syndrome includes administering to the subject a composition which includes an allogeneic haploidentical adipose tissue-derived stromal vascular fraction (SVF). The an allogeneic haploidentical adipose tissue-derived SVF may be produced by a process including centrifuging an allogeneic haploidentical adipose tissue lipoaspirate to obtain a packed adipose tissue, mixing the packed adipose tissue with collagenase, mincing the packed adipose tissue mixed with the collagenase by using a homogenizer, incubating the minced adipose tissue, centrifuging the incubated adipose tissue to separate and remove the collagenase, and repeating the centrifuging to obtain the stromal vascular fraction.

Provided herein are compositions containing genetically modified immune cells that express a ECM degrading enzyme, such as a matrix metallopeptidase. Overexpression of mature matrix metallopeptidase improves the tumor infiltrating capabilities of immune cells against solid tumors, including T-cells, tumor infiltrating lymphocytes, CAR macrophages, and NK cells (with and without a chimeric antigen receptor). Methods include administering CAR T or NK cells modified to express mature matrix metallopeptidase 8 to a subject with a solid tumor to improve the efficacy of the CAR T/NK cell therapy.

The present invention relates to a novel MMP-8 activation product such as a MMP-8 middle-part activation product. The invention also relates to detecting such a MMP-8 activation product or activated MMP-8 fragments in a biological sample derived from a subject and to the use thereof for diagnosing diseases which relate to abnormal or elevated levels of activated MMP-8.

A composition for treating Hutchinson-Gilford progeria syndrome according to an embodiment of the present invention includes a stromal vascular fraction (SVF). The stromal vascular fraction (SVF) may be produced by a process including centrifuging an allogeneic haploidentical adipose tissue lipoaspirate to obtain a packed adipose tissue, mixing the packed adipose tissue with collagenase, mincing the packed adipose tissue mixed with the collagenase by using a homogenizer, incubating the minced adipose tissue, centrifuging the incubated adipose tissue to separate and remove the collagenase, and repeating the centrifuging to obtain the stromal vascular fraction. A method of treating a subject with Hutchinson-Gilford progeria syndrome according to an embodiment of the present invention includes preparing allogeneic haploidentical adipose tissue-derived stromal vascular fraction (SVF) from a donor without Hutchinson-Gilford progeria syndrome, and administering to the subject the allogeneic haploidentical adipose tissue-derived stromal vascular fraction.

The present invention relates to a novel MMP-8 activation product such as a MMP-8 middle-part activation product. The invention also relates to detecting such a MMP-8 activation product or activated MMP-8 fragments in a biological sample derived from a subject and to the use thereof for diagnosing diseases which relate to abnormal or elevated levels of activated MMP-8.

MMP-8 activation products are disclosed that have a MMP-8 middle-part activation product having a size between 20-35 kDa. Methods of detecting the MMP-8 activation product or activated MMP-8 fragments in a biological sample derived from a subject are also disclosed. The MMP-8 activation product or activated MMP-8 fragments diagnose diseases based on abnormal or elevated levels of activated MMP-8.